South Korea-based ADEL said late on Monday that it has entered a $1.04 billion partnership with French drugmaker Sanofi to ...

Adel licenses ADEL‑Y01 to Sanofi for $1.04B Alzheimers program Adel signs $1.04 billion technology transfer with Sanofi for ...

Sanofi is back with its second pact of the day, this time announcing a licensing deal for a South Korean biotech’s antibody therapy designed to treat Alzheimer's disease. | Sanofi is back with its ...

Korean biopharmaceutical company Adel announced Monday that it has secured a license-out agreement worth up to $1.04 billion ...

ADEL Inc., a biopharma company, has entered into an exclusive worldwide license agreement with Sanofi for the development and ...

ADEL-Y01, a monoclonal antibody targeting tau protein, is in Phase I trials for Alzheimer's disease, developed by ADEL and ...

ADEL, Inc., a biopharmaceutical company dedicated to developing therapies for neurodegenerative diseases such as Alzheimer's ...

County officials approved a bid for the project much cheaper than expected. Two of three people involved with the fire have pleaded guilty.